This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Prevalence of Autoantibodies Associated with Thyroid and Celiac Disease in Ullrich-Turner Syndrome in Relation to Adult Height After Growth Hormone Treatment
A prospect i ve , multicenter study of patients with Ullrich-Turner syndrome ( UTS ) was conducted to estimate the prevalence of autoantibodies to tissue transglutaminase ( tTg ) , thyroid stimulating hormone receptor ( TSH-R ) , thyroglobulin ( TG ) and thyroid peroxidase ( TPO ) in relation to adult height after long-term growth hormone ( GH ) treatment . Out of 347 near-adult ( > 16 years ) patients with UTS from 96 German centers , whose longitudinal growth was documented within the Pharmacia International Growth Study ( KIGS ) , 188 returned for a st and ardized follow-up visit at a median chronological age of 18.7 ( 16.0 - 23.6 ) years ( bone age > 15 years ) . Serum sample s of 120 patients were obtained for central measurements of TSH , thyroxine ( T4 ) and free T4 and autoantibodies by st and ard immunoassays . Information regarding thyroid disease , karyotype and anthropometric data was extracted from the KIGS data base . Thirty-six percent of the patients with UTS had positive TG and /or TPO autoantibodies and 4 % had positive tTg autoantibodies , whereas 2 % had positive TG and /or TPO autoantibodies as well as positive tTg autoantibodies . TSH-R autoantibodies were undetectable in all patients . The detection of autoantibodies was unrelated to a specific karyotype . Median height st and ard deviation scores ( SDS , UTS ) at start of GH treatment ( 0.43 ; -1.07 , 1.85 ) and at follow-up ( 1.36 ; -0.11 , 2.57 ) were comparable in all patients independent of their antibody status . The total deltaheight SDS , however , was higher in patients with negative autoantibody titers ( 1.08 ; -0.03 , 2.25 ) compared to those with positive antibody titers ( 0.68 ; -0.44 , 1.82 ; p < 0.01 ) . Our study confirms the high prevalence of autoantibodies in patients with UTS predisposing them to autoimmune thyroid disease and celiac disease , and indicates for the first time that autoimmune pathologies may interfere with GH therapy and thus compromise final height . Therefore , medical care for patients with UTS should routinely include screening for these autoimmune disorders in order to assure early detection and appropriate treatment
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .